Targeting immune cells to treat triple-negative breast cancer
Targeting tumor-associated macrophages for triple-negative breast cancer treatment
This study is exploring new ways to treat triple-negative breast cancer by helping the immune system's cells fight the cancer more effectively, which could offer better options for patients who currently have few treatments available.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project ID | NIH-10988318 on NIH RePORTER |
What this research studies
This research focuses on developing new treatments for triple-negative breast cancer (TNBC), a particularly challenging type of breast cancer that lacks common therapeutic targets. The approach involves targeting tumor-associated macrophages, which are immune cells that can either promote or inhibit cancer growth. By blocking specific signals that allow cancer cells to evade the immune system, the research aims to enhance the ability of macrophages to attack and eliminate cancer cells. This innovative strategy could lead to more effective therapies for patients with TNBC who currently have limited treatment options.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with triple-negative breast cancer who have not responded well to existing therapies.
Not a fit: Patients with other types of breast cancer or those who have already exhausted all treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new and effective treatment option for patients with triple-negative breast cancer.
How similar studies have performed: Other research has shown promising results in targeting tumor-associated macrophages for cancer treatment, indicating that this approach has potential for success.
Where this research is happening
Duarte, United States
- Beckman Research Institute/city of Hope — Duarte, United States (Active)
Researchers
- Principal investigator: Feng, Mingye — Beckman Research Institute/city of Hope
- Study coordinator: Feng, Mingye
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.